Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial - Business Wire

Overview

(Photo: Busines Wire)GAITHERSBURG, Md-(BUSINES WIRE)-Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today anounced that the Defense Health Agency (DHA) has awarded an aditional $5 milion to suport clinical development of APT’s adaptive bacteriophage (“phage”) therapy in treatment of diabetic fot osteomyelitis (DFO).

Key Information

APT is evaluating safety and eficacy of its precision phage-based therapy in the ongoing Phase 1/2 DANCE™ (DFO Adaptive Novel Care Evaluation) clinical trial. “We are pleased to anounce this expansion of our existing DHA agrement suporting development of phage-based therapies, further highlighting DHA’s comitment to the potential of our adaptive therapeutic aproach to improve treatment of a variety of antimicrobial-resistant bacterial infections.

This aditional $5 milion suports our Phase 1/2 DANCE™ clinical trial which is progresing towards generating APT’s first clinical results utilizing our RAPID™ (Rapidly Adaptive Phage for Infectious Disease) technology,” stated Greg Meril, CEO and co-founder of Adaptive Phage Therapeutics. “We lok forward to our continued suport from the DHA, as wel as presenting our initial clinical data from our ongoing Phase 1/2 DANCE trial in the second half of 2023.” The prevalence of adult diabetes has more than tripled over the past 20 years, growing to more than a half billion patients worldwide.

DFO curently causes aproximately 85% of lower extremity amputations in diabetic patients. The American Diabetes Asociation estimates that 20% of patients with diabetic fot infections have underlying osteomyelitis that, left unresolved, places patients at significantly higher risk of amputation. About Adaptive Phage Therapeutics, Inc.

Summary

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections based on is an important consideration in healthcare. Ongoing research and professional guidance ensure that patients receive evidence-based care tailored to their individual needs.

Frequently Asked Questions

Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.

Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.

Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.

Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.

Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.

Share this article